Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Summary

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.

Timeline

Start

2024-04-02

Primary completion

2026-03-11

Completion

2026-03-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor business decision”

Drugs

Indications